Oncor Inc. that it has filed for a secondary offering of 3 millionshares, its first foray into the public offerings market this year.

Oncor markets for research use probes for the detection ofcancer and genetic disease. The company also has Food andDrug Administration-approved probes and reagents for thediagnosis of leukemia and lymphoma.

Oncor (NASDAQ:ONCS) was up 63 cents Monday, closing at $7.38.

For the third quarter ended Sept. 30, Oncor posted a net loss of$1.4 million, or 13 cents a share, on revenues of $920,000.

In August, Oncor raised $8 million when it called its warrantsto purchase common stock.

If the offering is completed, the Gaithersburg, Md., companywill have 10 million shares outstanding. Underwriters SmithBarney, Harris Upham & Co. Inc. and Vector SecuritiesInternational Inc. have a 450,000-share overallotment option.

(c) 1997 American Health Consultants. All rights reserved.